Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;9(7):103487.
doi: 10.1016/j.esmoop.2024.103487. Epub 2024 Jun 28.

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report

P Schöffski  1 , R L Jones  2 , M Agulnik  3 , J Y Blay  4 , A Chalmers  5 , A Italiano  6 , D Pink  7 , S Stacchiotti  8 , C Valverde  9 , B Vincenzi  10 , M J Wagner  11 , R Maki  12
Affiliations
Review

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report

P Schöffski et al. ESMO Open. 2024 Jul.

Abstract

Background: Locally advanced (unresectable) or metastatic dedifferentiated liposarcoma (DDLPS) is a common presentation of liposarcoma. Despite established diagnostic and treatment guidelines for DDLPS, critical clinical gaps remain driven by diagnostic challenges, symptom burden and the lack of targeted, safe and effective treatments. The objective of this study was to gather expert opinions from Europe and the United States on the management, unmet needs and expectations for clinical trial design as well as the value of progression-free survival (PFS) in this disease. Other aims included raising awareness and educate key stakeholders across healthcare systems.

Materials and methods: An international panel of 12 sarcoma key opinion leaders (KOLs) was recruited. The study consisted of two rounds of surveys with pre-defined statements. Experts scored each statement on a 9-point Likert scale. Consensus agreement was defined as ≥75% of experts scoring a statement with ≥7. Revised statements were discussed in a consensus meeting.

Results: Consensus was reached on 43 of 55 pre-defined statements across disease burden, treatment paradigm, unmet needs, value of PFS and its association with overall survival (OS), and cross-over trial design. Twelve statements were deprioritised or merged with other statements. There were no statements where experts disagreed.

Conclusion: This study constitutes the first international Delphi panel on DDLPS. It aimed to explore KOL perception of the disease burden and unmet need in DDLPS, the value of PFS, and its potential translation to OS benefit, as well as the relevance of a cross-over trial design for DDLPS therapies. Results indicate an alignment across Europe and the United States regarding DDLPS management, unmet needs, and expectations for clinical trials. Raising awareness of critical clinical gaps in relation to DDLPS can contribute to improving patient outcomes and supporting the development of innovative treatments.

Keywords: Delphi study; clinical trial design; dedifferentiated liposarcoma; progression-free survival; systemic therapy; unmet need.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowof key topics across each stage of the Delphi panel study. OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Brennan M.F., Antonescu C.R., Moraco N., Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260:416–421. - PMC - PubMed
    1. Nishio J., Nakayama S., Nabeshima K., Yamamoto T. Biology and management of dedifferentiated liposarcoma: state of the art and perspectives. J Clin Med. 2021;10:3230. - PMC - PubMed
    1. Gronchi A., Collini P., Miceli R., et al. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. Am J Surg Pathol. 2015;39:383–393. - PubMed
    1. Tseng W.W., Barretta F., Conti L., et al. Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Cancer. 2021;127:729–738. - PubMed
    1. Asano N., Yoshida A., Mitani S., et al. Frequent amplification of receptor tyrosine kinase genes in well-differentiated/dedifferentiated liposarcoma. Oncotarget. 2017;8 - PMC - PubMed

LinkOut - more resources